TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02854644

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional blood sample
Study: NCT00912002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: A single dose of 40 mg of \[14C\]MK-0941 (160 µCi), taken orally as eight 5-mg capsules
Study: NCT02745587

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: high dose external beam radiotherapy limited to the prostate(bed)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: high dose external beam radiotherapy limited to the prostate(bed)
Study: NCT03817775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: The intervention group will administer U sequence between 10 minutes prior to the beginning of the procedure until its end.
Study: NCT00814892

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic tumor cell vaccine
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: Given intradermally
Study: NCT01632995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC 200 mg/TDF 300 mg fixed-dose combination tablet
Description: Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.
Study: NCT04100889

Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study.
Study: NCT01325922

Intervention type: PROCEDURE
Group type: OTHER
Intervention: DFT Testing with a 50/50% tilt
Study: NCT00710476

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insemination
Description: Insemination with a lower concentration of spermatozoa: 150 000 spermatozoa/ml
Study: NCT00890032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BTSC mRNA-loaded DCs
Description: An escalating total dose of BTSC mRNA-loaded DCs (2x10\^6, 5x10\^6, and 2x10\^7 per vaccination) will be evaluated for purpose of establishing a maximum tolerated dose (MTD) and a dose-limiting toxicity (DLT).
Study: NCT01361776

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FSME-immune
Description: 0.5 ml im as scheduled in the 4 arms

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FSME-immune
Description: 0.5 ml im as scheduled in the 4 arms

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FSME-immune
Description: 0.5 ml im as scheduled in the 4 arms

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FSME-immune
Description: 0.5 ml im as scheduled in the 4 arms
Study: NCT00677014

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AV Delay programming through cardiac resynchronization therapy
Description: All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AV Delay programming through cardiac resynchronization therapy
Description: All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AV Delay programming through cardiac resynchronization therapy
Description: All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm.
Study: NCT00950768

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous transplantation
Description: Tandem autologous transplantation Melphalan 100 mg/m2 versus Melphalan 200 mg/m2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous transplantation
Description: Tandem autologous transplantation Melphalan 100 mg/m2 versus Melphalan 200 mg/m2
Study: NCT04338035

Intervention type: BEHAVIORAL
Intervention: Expectant management
Description: Patients did not undergo surgical treatment for endometriosis and medical consultations were done every 6 months from the beginning of the attempts to conceive
Study: NCT03115567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: 6 weeks of twice daily application of 0.1% triamcinolone cream to the face, chest, and back.
Study: NCT03898375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking with different optic flow speeds
Description: Patients will perform 4 sessions of 20 minutes treadmill walking: one control session without VR and 3 walking sessions with the VR. In each VR session, patients will walk with a different optic flow speed: the same as, faster than or slower than their walking speed.
Study: NCT03065907

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vision rehabilitation
Description: A service menu containing the minimum vision rehabilitation visits will be provided and assessed according to the participant's vision needs. Minimum vision rehabilitation visits include refraction, best-corrected visual acuity assessment, near vision, contrast sensitivity, central visual field test, education and consultation; rehabilitation visit will then be individualized.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vision rehabilitation
Description: A service menu containing the minimum vision rehabilitation visits will be provided and assessed according to the participant's vision needs. Minimum vision rehabilitation visits include refraction, best-corrected visual acuity assessment, near vision, contrast sensitivity, central visual field test, education and consultation; rehabilitation visit will then be individualized.
Study: NCT01513421

Intervention type: PROCEDURE
Intervention: Percutaneous drainage of intra-abdominal collection
Description: Percutaneous drainage of infected intra-abdominal collection Under computed tomography or ultrasound guidance.~Procedures perform by a board certified interventional radiologist

Intervention type: PROCEDURE
Intervention: Percutaneous drainage of intra-abdominal collection
Description: Percutaneous drainage of infected intra-abdominal collection Under computed tomography or ultrasound guidance.~Procedures perform by a board certified interventional radiologist
Study: NCT04398875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and standard care (ASC)
Description: A semi-standardized treatment protocol and standard care will be employed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture and standard care (SSC)
Description: Validated non-insertion sham acupuncture (Streitberger sham acupuncture) and standard care will be applied.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care (SC)
Description: Standard care will be employed.
Study: NCT02237521

Intervention type: OTHER
Intervention: Eu- and hyperglycemic clamp
Description: Eu- and hyperglycemic clamp with concomitant infusion of the natural occurring hormones glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) or placebo along with stable glucose isotope infusion to measure the effects of the incretins.

Intervention type: OTHER
Intervention: Eu- and hyperglycemic clamp
Description: Eu- and hyperglycemic clamp with concomitant infusion of the natural occurring hormones glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) or placebo along with stable glucose isotope infusion to measure the effects of the incretins.

Intervention type: OTHER
Intervention: Arginine test
Description: Bolus infusion of the natural occurring amino acid arginine to measure the ability to increase the secretion of insulin and glucagon

Intervention type: OTHER
Intervention: Arginine test
Description: Bolus infusion of the natural occurring amino acid arginine to measure the ability to increase the secretion of insulin and glucagon
Study: NCT00801177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: Cohort 2~200 mg I.V.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: Cohort 3~400 mg I.V.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: Cohort 4~600 mg I.V.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: Cohort 5~800 mg I.V.
Study: NCT02142777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S -Equol
Description: We will determine if the intervention (S-equol) alters platelet mitochondria COX activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo has no active ingredients but is made to look like the study drug.
Study: NCT04253795

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask
Description: After the laryngeal mask will be inserted lung isolation will be achieved with an artificial pneumothorax induced during opening the pleura, which resulted to the collapse of the nondependent lung with the patient's spontaneous breathing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: double lumen tube
Description: After the one lung ventilation will be started, lung isolation will be achieved by deflation of the nondependent lung.
Study: NCT00761514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humira (adalimumab)
Description: 40 mg eow
Study: NCT01040455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo once daily for eight weeks
Study: NCT03449095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol Target BAC .08%
Study: NCT03527121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESP physiotherapy
Description: A single session with advice and instructions from an ESP physiotherapist in rest, ice, compression and elevation AND pain guided early weight bearing plus a written home-based exercise program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: A single session with advice and instructions from a physician in rest, ice, compression and elevation (usual care group).
Study: NCT06537713

Intervention type: DIAGNOSTIC_TEST
Intervention: Testican-1
Description: Testican-1 and ubiquitin can serve as early indicators for diagnosing worsening clinical course and mortality in patients with moderate traumatic brain injury.

Intervention type: DIAGNOSTIC_TEST
Intervention: Testican-1
Description: Testican-1 and ubiquitin can serve as early indicators for diagnosing worsening clinical course and mortality in patients with moderate traumatic brain injury.
Study: NCT01485939

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch applied
Description: Patients in this group would applied the placebo patch after laparoscopic cholecystectomy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% lidocaine patch
Description: Patients in this group would applied the 5% lidocaine patch after laparoscopic cholecystectomy.
Study: NCT02775396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacle lens
Description: Wearing a spectacle lens design with corrective prescription power while playing computer game using an iPad tablet computer. Two lens designs were prescribed for each participant: the conventional single-vision lens and a new progressive addition lens designed for handheld digital device. Primary outcome measures were performed immediately after each lens delivery and one-month of lens wear.
Study: NCT01685827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifurtimox

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eflornithine
Study: NCT03381716

Intervention type: DRUG
Intervention: drug
Description: Application bracket

Intervention type: DRUG
Intervention: drug
Description: Application bracket

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery
Study: NCT01127568

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol is available in generic form as the Wyeth product under the trade name Inderal.
Description: The study medication will consist of a dose of 2/3 mg/Kg of short-acting propranolol or placebo, followed 2 hours later by a dose of 1 mg/Kg of long-acting or placebo. The medication will be prescribed by the clinic's physician after medical check-up. A nurse will monitor blood pressure. According to, 40 mg of short-acting propranolol dose should produce a peak blood level of approximately 25 ng/ml at 2 hours, which the additional 60 mg long-acting propranolol should further increase by no more than 5ng. The decay of the blood level induced by the 40 mg short-acting dose after its 2-hour peak will outstrip the further rise induced by the 60 mg long-acting proposal dose, so that blood levels will not rise above this peak 30 ng/ml, which is within the therapeutic clinical range. If the participant tolerates the combination dose without any difficulty, during subsequent sessions, both the short- and long-acting doses will be given together immediately after memory reactivation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol is available in generic form as the Wyeth product under the trade name Inderal.
Description: The study medication will consist of a dose of 2/3 mg/Kg of short-acting propranolol or placebo, followed 2 hours later by a dose of 1 mg/Kg of long-acting or placebo. The medication will be prescribed by the clinic's physician after medical check-up. A nurse will monitor blood pressure. According to, 40 mg of short-acting propranolol dose should produce a peak blood level of approximately 25 ng/ml at 2 hours, which the additional 60 mg long-acting propranolol should further increase by no more than 5ng. The decay of the blood level induced by the 40 mg short-acting dose after its 2-hour peak will outstrip the further rise induced by the 60 mg long-acting proposal dose, so that blood levels will not rise above this peak 30 ng/ml, which is within the therapeutic clinical range. If the participant tolerates the combination dose without any difficulty, during subsequent sessions, both the short- and long-acting doses will be given together immediately after memory reactivation.
Study: NCT04080193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-based interventional trial
Description: According to the SIRs the 12-week intervention will contain exercises from three out of six different key modules (e.g. self-efficacy, impulsivity). The remaining modules will be implemented as mini-modules during the end of the intervention phase. The study will be designed gender-sensitive instead of gender-dichotomous. This means that treatment contents will be individualized based on gender-related SIRs and not biological sex. Participants choose between two different styles of presentation for each module and the contents can be deepened within specific exercises.
Study: NCT04116996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEEP BRAIN STIMULATION
Description: NEUROMODULATION
Study: NCT05617976

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: caudal block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: caudal block
Study: NCT01439555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin, 40 mg per day orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Arginine
Description: L-Arginine, 2 Gm four times per day orally;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin
Description: Tetrahydrobiopterin 20 mg/kg/day orally
Study: NCT02655965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine 3.5 mg/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine 5µg/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Description: Sodium Chloride 0.9 %
Study: NCT02244502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100L(O)
Description: Patients will be treated continuously with the NovoTTF-100L(O). NovoTTF-100L(O) treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 over 1 hour infusion will be administered weekly for 8 weeks and then on days 1, 8, 15 of each subsequent 28 day cycle.
Study: NCT02598375

Intervention type: OTHER
Intervention: Feeding intolerance
Description: In this study ; it is aimed to show the value of IFABP regarding the identifying the feeding intolerance and early detection of enteral feeding intolerance

Intervention type: OTHER
Intervention: Feeding intolerance
Description: In this study ; it is aimed to show the value of IFABP regarding the identifying the feeding intolerance and early detection of enteral feeding intolerance
Study: NCT00542256

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy
Description: 14 days of constraint induced movement therapy with 10 weekdays of up to 6 hours of training of the affected arm combined with application of tDCS over the primary motor cortex for 40 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy
Description: 14 days of constraint induced movement therapy with 10 days of up to 6 hours of training in the affected arm and sham tDCS applied over the primary motor cortex for 40 minutes with active current applied for 30 seconds.
Study: NCT04227366

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-089
Description: BCD-089 162 mg SC

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexat
Description: 15 to 25 mg/week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexat
Description: 15 to 25 mg/week
Study: NCT03295162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg
Description: Melatonin will be given at a total dose of 20 mg dissolved in 4 ml of distilled water via enteral route in two doses of 10 mg each(2 ml ), with a 1-hour interval. to one group together with conventional treatment

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conventional treatment of neonatal sepsis
Description: Conventional treatment of neonatal sepsis including antibiotics,IV fluids, Total Parenteral Nutrition,etc...

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment of neonatal sepsis
Description: Conventional treatment of neonatal sepsis including antibiotics,IV fluids, Total Parenteral Nutrition,etc...
Study: NCT02284126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Topically applied powder and paste to surgical site at time of closure.
Study: NCT03473574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: immune checkpoint inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: immune checkpoint inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: immune checkpoint inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: immune checkpoint inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: standard chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: standard chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: standard chemotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: immune checkpoint inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: immune checkpoint inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: immune checkpoint inhibitor
Study: NCT00000421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00621478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lorazepam or diazepam
Description: Administration instructions will ask to deliver 0.04 ml per kilogram of child's weight of the study medication up to a maximum of 1.6 ml. 0.04 ml/kg (maximum dose 1.6 ml) will deliver 0.1 mg/kg of lorazepam (maximum dose 4 mg) and 0.2 mg/kg of diazepam (maximum dose 8 mg). Half of this dose can be repeated in 5 minutes if the patient is still convulsing.~The medication will be administered as a slow IV push.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lorazepam or diazepam
Description: Administration instructions will ask to deliver 0.04 ml per kilogram of child's weight of the study medication up to a maximum of 1.6 ml. 0.04 ml/kg (maximum dose 1.6 ml) will deliver 0.1 mg/kg of lorazepam (maximum dose 4 mg) and 0.2 mg/kg of diazepam (maximum dose 8 mg). Half of this dose can be repeated in 5 minutes if the patient is still convulsing.~The medication will be administered as a slow IV push.